Skip to main content
رجوع
Watch Compare

Liminatus Pharma, Inc.

جودة البيانات: 83%
مُدرج أيضًا باسم LIMNW Nasdaq
LIMN
Nasdaq Manufacturing Chemicals
KWD 0.21
▲ KWD 0.02 (11.96%)
القيمة السوقية: 9.24 M
السعر
KWD 0.21
القيمة السوقية
9.24 M
نطاق اليوم
KWD 0.18 — KWD 0.21
نطاق 52 أسبوعًا
KWD 0.16 — KWD 33.66
حجم التداول
2,463,237
فتح KWD 0.18
متوسط 50 يوم / 200 يوم
KWD 0.45
54.32% below
متوسط 50 يوم / 200 يوم
KWD 2.58
92.01% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -9.98 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio0.42
Interest Coverage-13.75

التقييم

PE (TTM)
-0.91
أعلى من متوسط القطاع (-1.98)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (44 نظير)
المقياس السهم وسيط القطاع
P/E -0.9 -2.0
P/B — 5.1
ROE % — -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -10.21 M
ROE N/A ROA -627.86%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -9.98 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.42
Interest Coverage -13.75 Asset Turnover N/A
Working Capital -1.66 M Tangible Book Value -1.65 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.91 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -107.91%
Market Cap 9.24 M Enterprise Value 10.69 M
Per Share
EPS (Diluted TTM) -0.43 Revenue / Share N/A
FCF / Share -0.22 OCF / Share -0.22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 97.75%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue —
Net Income -10.21 M
EPS (Diluted) -0.43
Gross Profit —
Operating Income -2.97 M
EBITDA —
R&D Expenses 2.69 M
SG&A Expenses —
D&A —
Interest Expense 215,903.0
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 512,795.0
Total Liabilities 10.33 M
Shareholders' Equity -9.81 M
Total Debt 1.44 M
Cash & Equivalents —
Current Assets 500,574.0
Current Liabilities 10.30 M